Therefore, the cervical cancer PDX models conserved the somatic mutations of FAT1 in original cervical cancer, and the mutated FAT1 gene could be utilized as the molecular target of new therapeutic regimens for cervical cancer patients. This evidence concerns the gene FAT1 and cervical cancer.